Abstract
Introduction: Atezolizumab plus bevacizumab (Atez/Bev) is a standard treatment for unresectable hepatocellular carcinoma (HCC) due to its good antitumor and survival prolongation effects. Post-progression survival (PPS) has been reported to be a great contributor in the treatment with tyrosine kinase inhibitors for unresectable HCC. This study aimed to clarify the significance of progression-free survival (PFS) or PPS of Atez/Bev treatment for HCC. Methods: We analyzed the correlations of PFS and PPS with overall survival (OS) in studies of HCC patients treated with Atez/Bev and evaluated the contribution to OS in Atez/Bev treatment with patients at our institutions as clinical practice. Results: Analysis of 18 studies involving 3,752 patients treated with Atez/Bev found that PPS had a stronger correlation with OS (R2 = 0.872, p < 0.001) than did PFS (R2 = 0.605, p = 0.001). Analysis of 80 patients with unresectable HCC treated with Atez/Bev found that presence of antitumor responses during Atez/Bev was the most significant contributor to OS, and post-progression treatment after Atez/Bev also significantly contribute to OS. Conclusion: The presence of antitumor response with tumor shrinkage during Atez/Bev treatment contributes to good OS through its durable response. Atez/Bev treatment could be considered as first-line treatment for unresectable HCC. However, there is a need for optimal biomarkers for good antitumor response.
Journal Section:
Clinical Study
References
1.
Devarbhavi
H
, Asrani
SK
, Arab
JP
, Nartey
YA
, Pose
E
, Kamath
PS
. Global burden of liver disease: 2023 update
. J Hepatol
. 2023
;79
(2
):516
–37
.2.
Forner
A
, Llovet
JM
, Bruix
J
. Hepatocellular carcinoma
. Lancet
. 2012
;379
(9822
):1245
–55
.3.
Llovet
JM
, Ricci
S
, Mazzaferro
V
, Hilgard
P
, Gane
E
, Blanc
JF
. Sorafenib in advanced hepatocellular carcinoma
. N Engl J Med
. 2008
;359
(4
):378
–90
.4.
Kudo
M
, Finn
RS
, Qin
S
, Han
KH
, Ikeda
K
, Piscaglia
F
. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
. Lancet
. 2018
;391
(10126
):1163
–73
.5.
Finn
RS
, Qin
S
, Ikeda
M
, Galle
PR
, Ducreux
M
, Kim
TY
. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma
. N Engl J Med
. 2020
;382
(20
):1894
–905
.6.
Kudo
M
. Durvalumab plus tremelimumab in unresectable hepatocellular carcinoma
. Hepatobiliary Surg Nutr
. 2022
;11
(4
):592
–6
.7.
Terashima
T
, Yamashita
T
, Takata
N
, Nakagawa
H
, Toyama
T
, Arai
K
. Post-progression survival and progression-free survival in patients with advanced hepatocellular carcinoma treated by sorafenib
. Hepatol Res
. 2016
;46
(7
):650
–6
.8.
Finn
RS
, Merle
P
, Granito
A
, Huang
YH
, Bodoky
G
, Pracht
M
. Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: additional analyses from the phase III RESORCE trial
. J Hepatol
. 2018
;69
(2
):353
–8
.9.
Pfister
D
, Nunez
NG
, Pinyol
R
, Govaere
O
, Pinter
M
, Szydlowska
M
. NASH limits anti-tumour surveillance in immunotherapy-treated HCC
. Nature
. 2021
;592
(7854
):450
–6
.10.
Anstee
QM
, Reeves
HL
, Kotsiliti
E
, Govaere
O
, Heikenwalder
M
. From NASH to HCC: current concepts and future challenges
. Nat Rev Gastroenterol Hepatol
. 2019
;16
(7
):411
–28
.11.
Zhang
L
, Feng
J
, Kuang
T
, Chai
D
, Qiu
Z
, Deng
W
. Blood biomarkers predict outcomes in patients with hepatocellular carcinoma treated with immune checkpoint Inhibitors: a pooled analysis of 44 retrospective sudies
. Int Immunopharmacol
. 2023
;118
:110019
.12.
Hiraoka
A
, Kumada
T
, Tsuji
K
, Takaguchi
K
, Itobayashi
E
, Kariyama
K
. Validation of modified ALBI grade for more detailed assessment of hepatic function in hepatocellular carcinoma patients: a multicenter analysis
. Liver Cancer
. 2019
;8
(2
):121
–9
.13.
Kudo
M
, Kawamura
Y
, Hasegawa
K
, Tateishi
R
, Kariyama
K
, Shiina
S
. Management of hepatocellular carcinoma in Japan: JSH consensus statements and recommendations 2021 update
. Liver Cancer
. 2021
;10
(3
):181
–223
.14.
Kudo
M
, Han
KH
, Ye
SL
, Zhou
J
, Huang
YH
, Lin
SM
. A changing paradigm for the treatment of intermediate-stage hepatocellular carcinoma: asia-pacific primary liver cancer expert consensus statements
. Liver Cancer
. 2020
;9
(3
):245
–60
.15.
Cheng
AL
, Qin
S
, Ikeda
M
, Galle
PR
, Ducreux
M
, Kim
TY
. Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma
. J Hepatol
. 2022
;76
(4
):862
–73
.16.
Fulgenzi
CAM
, Cheon
J
, D’Alessio
A
, Nishida
N
, Ang
C
, Marron
TU
. Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: results of the AB-real study
. Eur J Cancer
. 2022
;175
:204
–13
.17.
Charonpongsuntorn
C
, Tanasanvimon
S
, Korphaisarn
K
, Payapwattanawong
S
, Siripoon
T
, Pakvisal
N
. Efficacy, safety, and patient-reported outcomes of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma in Thailand: a multicenter prospective study
. JCO Glob Oncol
. 2022
;8
:e2200205
.18.
D’Alessio
A
, Fulgenzi
CAM
, Nishida
N
, Schonlein
M
, von Felden
J
, Schulze
K
. Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: a real-world study
. Hepatology
. 2022
;76
(4
):1000
–12
.19.
Vithayathil
M
, D’Alessio
A
, Fulgenzi
CAM
, Nishida
N
, Schonlein
M
, von Felden
J
. Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma
. Liver Int
. 2022
;42
(11
):2538
–47
.20.
Rimini
M
, Rimassa
L
, Ueshima
K
, Burgio
V
, Shigeo
S
, Tada
T
. Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis
. ESMO Open
. 2022
;7
(6
):100591
.21.
Wu
YL
, Fulgenzi
CAM
, D’Alessio
A
, Cheon
J
, Nishida
N
, Saeed
A
. Neutrophil-to-Lymphocyte and platelet-to-lymphocyte ratios as prognostic biomarkers in unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab
. Cancers
. 2022
;14
(23
):5834
.22.
Casadei-Gardini
A
, Rimini
M
, Tada
T
, Suda
G
, Shimose
S
, Kudo
M
. Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population
. Eur J Cancer
. 2023
;180
:9
–20
.23.
Teng
W
, Lin
CC
, Su
CW
, Lin
PT
, Hsieh
YC
, Chen
WT
. Combination of CRAFITY score with Alpha-fetoprotein response predicts a favorable outcome of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma
. Am J Cancer Res
. 2022
;12
(4
):1899
–911
.24.
Shao
YY
, Feng
YH
, Yen
CJ
, Yang
TS
, Shen
YC
, Chao
Y
. Bevacizumab and atezolizumab as first-line therapy for advanced hepatocellular carcinoma: a Taiwanese subgroup analysis on efficacy and safety
. J Formos Med Assoc
. 2022
;121
(12
):2430
–7
.25.
Awiwi
MO
, Elsayes
KM
, Mohamed
YI
, Altameemi
L
, Gjoni
M
, Irshad
OM
. The prognostic value of baseline clinical and radiologic imaging features in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab
. J Hepatocell Carcinoma
. 2022
;9
:913
–27
.26.
Mohamed
YI
, Duda
DG
, Awiwi
MO
, Lee
SS
, Altameemi
L
, Xiao
L
. Plasma growth hormone is a potential biomarker of response to atezolizumab and bevacizumab in advanced hepatocellular carcinoma patients
. Oncotarget
. 2022
;13
:1314
–21
.27.
Himmelsbach
V
, Pinter
M
, Scheiner
B
, Venerito
M
, Sinner
F
, Zimpel
C
. Efficacy and safety of atezolizumab and bevacizumab in the real-world treatment of advanced hepatocellular carcinoma: experience from four tertiary centers
. Cancers
. 2022
;14
(7
):1722
.28.
Sinner
F
, Pinter
M
, Scheiner
B
, Ettrich
TJ
, Sturm
N
, Gonzalez-Carmona
MA
. Atezolizumab plus bevacizumab in patients with advanced and progressing hepatocellular carcinoma: retrospective multicenter experience
. Cancers
. 2022
;14
(23
):5966
.29.
Tanaka
T
, Hiraoka
A
, Tada
T
, Hirooka
M
, Kariyama
K
, Tani
J
. Therapeutic efficacy of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma in patients with Child-Pugh class A or B liver function in real-world clinical practice
. Hepatol Res
. 2022
;52
(9
):773
–83
.30.
Tada
T
, Kumada
T
, Hiraoka
A
, Hirooka
M
, Kariyama
K
, Tani
J
. Safety and efficacy of atezolizumab plus bevacizumab in elderly patients with hepatocellular carcinoma: a multicenter analysis
. Cancer Med
. 2022
;11
(20
):3796
–808
.31.
Campani
C
, Bamba-Funck
J
, Campion
B
, Sidali
S
, Blaise
L
, Ganne-Carrie
N
. Baseline ALBI score and early variation of serum AFP predicts outcomes in patients with HCC treated by atezolizumab-bevacizumab
. Liver Int
. 2023
;43
(3
):708
–17
.32.
de Castro
T
, Jochheim
LS
, Bathon
M
, Welland
S
, Scheiner
B
, Shmanko
K
. Atezolizumab and bevacizumab in patients with advanced hepatocellular carcinoma with impaired liver function and prior systemic therapy: a real-world experience
. Ther Adv Med Oncol
. 2022
;14
:17588359221080298
.33.
Tajiri
K
, Tokimitsu
Y
, Kawai
K
, Motofuji
Y
, Shinno
E
, Kashii
Y
. Impact of post-progression survival on outcomes of lenvatinib treatment for unresectable hepatocellular carcinoma: a systematic review and retrospective cohort study
. Anticancer Res
. 2022
;42
(12
):6007
–18
.34.
Kudo
M
. Prioritized requirements for first-line systemic therapy for hepatocellular carcinoma: broad benefit with less toxicity
. Liver Cancer
. 2023
;12
(1
):1
–6
.35.
Chen
DS
, Mellman
I
. Oncology meets immunology: the cancer-immunity cycle
. Immunity
. 2013
;39
(1
):1
–10
.36.
Hegde
PS
, Chen
DS
. Top 10 challenges in cancer immunotherapy
. Immunity
. 2020
;52
(1
):17
–35
.37.
Storandt
MH
, Mahipal
A
, Tella
SH
, Kommalapati
A
, Jin
Z
. Systemic therapy in advanced hepatocellular carcinoma: patient selection and key considerations
. J Hepatocell Carcinoma
. 2022
;9
:1187
–200
.38.
Llovet
JM
, Pinyol
R
, Kelley
RK
, El-Khoueiry
A
, Reeves
HL
, Wang
XW
. Molecular pathogenesis and systemic therapies for hepatocellular carcinoma
. Nat Cancer
. 2022
;3
(4
):386
–401
.39.
Bejjani
AC
, Finn
RS
. Hepatocellular carcinoma: pick the winner-tyrosine kinase inhibitor versus immuno-oncology agent-based combinations
. J Clin Oncol
. 2022
;40
(24
):2763
–73
.40.
Talbot
T
, D’Alessio
A
, Pinter
M
, Balcar
L
, Scheiner
B
, Marron
TU
. Progression patterns and therapeutic sequencing following immune checkpoint inhibition for hepatocellular carcinoma: an international observational study
. Liver Int
. 2023
;43
(3
):695
–707
.41.
Kudo
M
. Sequential therapy for hepatocellular carcinoma after failure of atezolizumab plus bevacizumab combination therapy
. Liver Cancer
. 2021
;10
(2
):85
–93
.42.
Albarrak
J
, Al-Shamsi
H
. Current status of management of hepatocellular carcinoma in the gulf region: challenges and recommendations
. Cancers
. 2023
;15
(7
):2001
.43.
Girardi
DM
, Sousa
LP
, Miranda
TA
, Haum
FNC
, Pereira
GCB
, Pereira
AAL
. Systemic therapy for advanced hepatocellular carcinoma: current stand and perspectives
. Cancers
. 2023
;15
(6
):1680
.44.
Zhu
AX
, Abbas
AR
, de Galarreta
MR
, Guan
Y
, Lu
S
, Koeppen
H
. Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma
. Nat Med
. 2022
;28
(8
):1599
–611
.45.
Yang
H
, Kang
B
, Ha
Y
, Lee
SH
, Kim
I
, Kim
H
. High serum IL-6 correlates with reduced clinical benefit of atezolizumab and bevacizumab in unresectable hepatocellular carcinoma
. JHEP Rep
. 2023
;5
(4
):100672
.46.
Giovannini
C
, Suzzi
F
, Tovoli
F
, Bruccoleri
M
, Marseglia
M
, Alimenti
E
. Low-baseline PD1+ granulocytes predict responses to atezolizumab-bevacizumab in hepatocellular carcinoma
. Cancers
. 2023
;15
(6
):1661
.47.
Tada
T
, Kumada
T
, Hiraoka
A
, Kariyama
K
, Tani
J
, Hirooka
M
. New prognostic system based on inflammation and liver function predicts prognosis in patients with advanced unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab: a validation study
. Cancer Med
. 2023
;12
(6
):6980
–93
.© 2023 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2023
You do not currently have access to this content.
